230 related articles for article (PubMed ID: 19707323)
1. Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.
Mesa RA
Biologics; 2007 Jun; 1(2):129-38. PubMed ID: 19707323
[TBL] [Abstract][Full Text] [Related]
2. Oncogenes in myeloproliferative disorders.
Tefferi A; Gilliland DG
Cell Cycle; 2007 Mar; 6(5):550-66. PubMed ID: 17351342
[TBL] [Abstract][Full Text] [Related]
3. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
Cortes J; Kantarjian H
Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
[TBL] [Abstract][Full Text] [Related]
4. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
5. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
6. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
Tefferi A; Thiele J; Vardiman JW
Cancer; 2009 Sep; 115(17):3842-7. PubMed ID: 19472396
[TBL] [Abstract][Full Text] [Related]
7. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
[TBL] [Abstract][Full Text] [Related]
8. Kinase drug discovery approaches in chronic myeloproliferative disorders.
Kumar C; Purandare AV; Lee FY; Lorenzi MV
Oncogene; 2009 Jun; 28(24):2305-13. PubMed ID: 19421140
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms.
Bisen A; Claxton DF
Adv Exp Med Biol; 2013; 779():179-96. PubMed ID: 23288640
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of mast cells in myeloproliferative disorders and myelodysplastic syndromes.
Dunphy CH
Arch Pathol Lab Med; 2005 Feb; 129(2):219-22. PubMed ID: 15679425
[TBL] [Abstract][Full Text] [Related]
11. bcr/abl-negative, classic myeloproliferative disorders: diagnosis and treatment.
Tefferi A; Barbui T
Mayo Clin Proc; 2005 Sep; 80(9):1220-32. PubMed ID: 16178503
[TBL] [Abstract][Full Text] [Related]
12. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.
Vainchenker W; Constantinescu SN
Hematology Am Soc Hematol Educ Program; 2005; ():195-200. PubMed ID: 16304380
[TBL] [Abstract][Full Text] [Related]
13. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C
Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic signals as treatment targets in classic myeloproliferative neoplasms.
Tefferi A; Levine RL; Kantarjian H
Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):114-9. PubMed ID: 19147089
[TBL] [Abstract][Full Text] [Related]
15. Application of tyrosine kinase inhibitors as a promising targeting treatment for myeloproliferative neoplasms --- review.
Wei M; Gao CJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):1064-70. PubMed ID: 21867645
[TBL] [Abstract][Full Text] [Related]
16. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders.
Pardanani A; Tefferi A
Blood; 2004 Oct; 104(7):1931-9. PubMed ID: 15166033
[TBL] [Abstract][Full Text] [Related]
17. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
18. The expression of Death Inducer-Obliterator (DIDO) variants in Myeloproliferative Neoplasms.
Berzoti-Coelho MG; Ferreira AF; de Souza Nunes N; Pinto MT; Júnior MC; Simões BP; Martínez-A C; Souto EX; Panepucci RA; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2016 Jul; 59():25-30. PubMed ID: 27282563
[TBL] [Abstract][Full Text] [Related]
19. A Case of Chronic Myelogenous Leukemia Occurring in a Patient Treated for Essential Thrombocythemia.
Hassankrishnamurthy S; Mody MD; Kota VK
Am J Case Rep; 2019 Jan; 20():10-14. PubMed ID: 30602717
[TBL] [Abstract][Full Text] [Related]
20. The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers.
Haferlach T; Bacher U; Kern W; Schnittger S; Haferlach C
Ann Hematol; 2008 Jan; 87(1):1-10. PubMed ID: 17938925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
